(NTRA) Natera - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6323071042

Panorama, Horizon, Vistara, Spectrum, Signatera

Stock: Biotechnology
Age 10.6y

MCap 33,515m
Avg Vol 1.05M (251M USD)

Beta 1.167
Volatility 39.14%

EPS (Earnings per Share)

EPS CAGR: 98.92%
EPS Trend: 85.6%

Last SUE: 2.23
Qual. Beats: 1

Revenue

Rev. CAGR: 38.83%
Rev. Trend: 99.3%

Last SUE: 3.26
Qual. Beats: 11

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	39.1%
Value at Risk 5%th	59.5%
Relative Tail Risk	-7.61%

Reward TTM
Sharpe Ratio	0.96
Alpha	27.54
CAGR/Max DD	1.99

Character TTM
Hurst Exponent	0.594
Beta	1.167
Beta Downside	0.903

Drawdowns 3y
Max DD	39.94%
Mean DD	8.21%
Median DD	5.78%

Description: NTRA Natera December 19, 2025

Natera, Inc. (NASDAQ: NTRA) is a global molecular diagnostics firm that commercializes a portfolio of DNA-based tests spanning reproductive health, oncology, organ transplantation, and rare-disease screening. Core offerings include Panorama (non-invasive prenatal testing), Signatera (personalized circulating tumor DNA monitoring), and a suite of carrier-screening, pre-implantation genetic testing, and transplant-rejection assays, delivered through a mix of direct sales and partner laboratories. Strategic collaborations with BGI Genomics and Foundation Medicine expand its next-generation sequencing (NGS) capabilities and market reach.

Key performance indicators from the most recent fiscal year show revenue of roughly $1.0 billion, up about 20 % year-over-year, driven primarily by strong growth in the Panorama and Signatera lines. The company maintains an industry-leading gross margin near 80 % and reported cash and short-term investments of approximately $400 million, providing runway for R&D and potential acquisitions. Sector-wide, the NIPT market is projected to expand at a CAGR of ~10 % through 2029, while oncology-focused liquid biopsy adoption is accelerating as payers broaden reimbursement for personalized cancer monitoring.

For a deeper quantitative assessment of NTRA’s valuation metrics, the ValueRay platform offers a concise, data-driven dashboard worth reviewing.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income: -309.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 7.22 > 1.0
NWC/Revenue: 47.49% < 20% (prev 66.66%; Δ -19.16% < -1%)
CFO/TA 0.11 > 3% & CFO 194.3m > Net Income -309.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.27 > 1.5 & < 3
Outstanding Shares: last quarter (137.2m) vs 12m ago 10.84% < -2%
Gross Margin: 63.70% > 18% (prev 0.58%; Δ 6312 % > 0.5%)
Asset Turnover: 124.1% > 50% (prev 96.29%; Δ 27.76% > 0%)
Interest Coverage Ratio: -69.90 > 6 (EBITDA TTM -268.8m / Interest Expense TTM 4.37m)

Altman Z'' (< 1.1 .. > 2.6) -7.84

A: 0.55 (Total Current Assets 1.45b - Total Current Liabilities 442.0m) / Total Assets 1.82b
B: -1.55 (Retained Earnings -2.82b / Total Assets 1.82b)
C: -0.18 (EBIT TTM -305.5m / Avg Total Assets 1.71b)
D: -4.96 (Book Value of Equity -2.82b / Total Liabilities 569.3m)
Altman-Z'' Score: -7.84= D

ValueRay F-Score (Strict, 0-100) 49.96

1. Piotroski: 4.50pt
2. FCF Yield: 0.29%
3. FCF Margin: 4.42%
4. Debt/Equity: 0.15
5. Debt/Ebitda: data missing
6. ROIC - WACC: -28.58%
7. RoE: -25.07%
8. Revenue Trend: 99.30%
9. EPS Trend: 85.60%

What is the price of NTRA shares?

As of January 23, 2026, the stock is trading at USD 242.91 with a total of 971,270 shares traded.
Over the past week, the price has changed by +1.50%, over one month by +3.06%, over three months by +29.91% and over the past year by +44.98%.

Is NTRA a buy, sell or hold?

Natera has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NTRA.

Strong Buy: 12
Buy: 8
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the NTRA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	257	5.8%
Analysts Target Price	257	5.8%
ValueRay Target Price	341.9	40.7%

NTRA Fundamental Data Overview January 17, 2026

P/S = 15.8339
P/B = 26.7653
Revenue TTM = 2.12b USD
EBIT TTM = -305.5m USD
EBITDA TTM = -268.8m USD
Long Term Debt = 118.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 80.3m USD (from shortTermDebt, last quarter)
Debt = 184.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -856.7m USD (from netDebt column, last quarter)
Enterprise Value = 32.66b USD (33.52b + Debt 184.7m - CCE 1.04b)
Interest Coverage Ratio = -69.90 (Ebit TTM -305.5m / Interest Expense TTM 4.37m)
EV/FCF = 349.0x (Enterprise Value 32.66b / FCF TTM 93.6m)
FCF Yield = 0.29% (FCF TTM 93.6m / Enterprise Value 32.66b)
FCF Margin = 4.42% (FCF TTM 93.6m / Revenue TTM 2.12b)
Net Margin = -14.61% (Net Income TTM -309.2m / Revenue TTM 2.12b)
Gross Margin = 63.70% ((Revenue TTM 2.12b - Cost of Revenue TTM 768.4m) / Revenue TTM)
Gross Margin QoQ = 64.91% (prev 63.50%)
Tobins Q-Ratio = 17.93 (Enterprise Value 32.66b / Total Assets 1.82b)
Interest Expense / Debt = 0.57% (Interest Expense 1.04m / Debt 184.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -241.4m (EBIT -305.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.27 (Total Current Assets 1.45b / Total Current Liabilities 442.0m)
Debt / Equity = 0.15 (Debt 184.7m / totalStockholderEquity, last quarter 1.25b)
Debt / EBITDA = 3.19 (negative EBITDA) (Net Debt -856.7m / EBITDA -268.8m)
Debt / FCF = -9.16 (Net Debt -856.7m / FCF TTM 93.6m)
Total Stockholder Equity = 1.23b (last 4 quarters mean from totalStockholderEquity)
RoA = -18.12% (Net Income -309.2m / Total Assets 1.82b)
RoE = -25.07% (Net Income TTM -309.2m / Total Stockholder Equity 1.23b)
RoCE = -22.60% (EBIT -305.5m / Capital Employed (Equity 1.23b + L.T.Debt 118.4m))
RoIC = -18.37% (negative operating profit) (NOPAT -241.4m / Invested Capital 1.31b)
WACC = 10.21% (E(33.52b)/V(33.70b) * Re(10.26%) + D(184.7m)/V(33.70b) * Rd(0.57%) * (1-Tc(0.21)))
Discount Rate = 10.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.23%
[DCF Debug] Terminal Value 60.98% ; FCFF base≈93.6m ; Y1≈61.4m ; Y5≈28.0m
Fair Price DCF = 9.00 (EV 398.2m - Net Debt -856.7m = Equity 1.25b / Shares 139.4m; r=10.21% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 85.60 | EPS CAGR: 98.92% | SUE: 2.23 | # QB: 1
Revenue Correlation: 99.30 | Revenue CAGR: 38.83% | SUE: 3.26 | # QB: 11
EPS next Quarter (2026-03-31): EPS=-0.59 | Chg30d=+0.003 | Revisions Net=-1 | Analysts=12
EPS next Year (2026-12-31): EPS=-1.96 | Chg30d=-0.007 | Revisions Net=-1 | Growth EPS=+19.4% | Growth Revenue=+17.2%

Additional Sources for NTRA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle